Polycystic Ovary Syndrome and Chronic Inflammation: Pharmacotherapeutic Implications
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Objective: To examine the relationship between polycystic ovary syndrome (PCOS), cardiovascular risk factors, cardiovascular disease (CVD), and chronic inflammation and analyze data regarding pharmacologic therapies that are recommended to reduce CVD risk in PCOS and the impact of those therapies on chronic inflammation. Data Sources: A search of MEDLINE (1950-October 2011) was conducted to identify clinical studies pertaining to the identification and treatment of CVD and chronic low-grade inflammation in PCOS, Search terms included polycystic ovary syndrome, cardiovascular disease, inflammation, metformin, thiazolidinedione, and statin. Bibliographies of these studies and review articles were also examined. Study Selection and Data Extraction: English-language clinical studies evaluating the effect of metformin, thiazolidinediones, and statins on inflammatory markers, endothelial function, adhesion molecules, fibrinolysis, cytokines, and adipokines in PCOS were included. Data Synthesis: Women with PCOS have an increased prevalence of many cardiovascular risk factors including obesity, android fat distribution, insulin resistance, impaired glucose tolerance, diabetes, dyslipidemia, hypertension, and metabolic syndrome. Markers of chronic low-grade inflammation, which are associated with an increased risk of CVD, are also elevated in PCOS. Clinical guidelines recommend the use of insulin sensitizers and statins to prevent CVD in some patients with PCOS. Current literature indicates that each of these medication classes has beneficial effects on inflammation, as well. Although there are currently no studies to determine whether these treatments decrease CVD in PCOS, it can be hypothesized that drugs impacting chronic inflammation may reduce cardiovascular risk. Some studies show that metformin, thiazolidinediones, and statins have beneficial effects on inflammatory markers in PCOS; however, the data are inconsistent. Conclusions: There is insufficient information to recommend any pharmacologic therapies for their antiinflammatory effects in PCOS in the absence of other indications such as diabetes and dyslipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Esposito, K., Pontillo, A., Di Palo, C., Giugliano, G., Masella, M., Marfella, R., & Giugliano, D. (2003) · JAMA · doi:10.1001/jama.289.14.1799 · Cited by 1,511
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Andrology: Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients
Balen, A. H., Conway, G. S., Kaltsas, G., Techatraisak, K., Manning, P. J., West, C., & Jacobs, H. S. (1995) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a136243 · Cited by 1,060
Wild, S., Pierpoint, T., McKeigue, P., & Jacobs, H. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01000.x · Cited by 970
Ridker, P. M., Rifai, N., Pfeffer, M., Sacks, F., Lepage, S., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.101.18.2149 · Cited by 934
Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1045 · Cited by 931
Prediction of coronary events with electron beam computed tomography
Arad, Y., Spadaro, L. A., Goodman, K., Newstein, D., & Guerci, A. D. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00872-x · Cited by 744
Low grade chronic inflammation in women with polycystic ovarian syndrome
Kelly, C. C. J., Lyall, H., Petrie, J. R., Gould, G. W., Connell, J. M. C., & Sattar, N. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7580 · Cited by 640
Cited by
Cooney, L. G., Lee, I., Sammel, M. D., & Dokras, A. (2017) · Human Reproduction · doi:10.1093/humrep/dex044 · Cited by 631
Epidemiology and Comorbidities of Polycystic Ovary Syndrome in an Indigent Population
Sirmans, S. M., Parish, R. C., Blake, S., & Wang, X. (2014) · Journal of Investigative Medicine · doi:10.1097/01.jim.0000446834.90599.5d · Cited by 79
“It is also associated with an increased risk for cardiovascular disease (CVD), glucose intolerance, diabetes,(9,10) and a clustering of cardiovascular risk factors.(11) A number of other comorbidities have been identified in the literature, including depression,(12) anxiety,(13) bipolar disorder,(14) eating disorders,…”
BackgroundSelf-citationVine, D., Ghosh, M., Wang, T., & Bakal, J. (2024) · CJC Open · doi:10.1016/j.cjco.2023.12.010 · Cited by 53
Ferreira, S. R., Goyeneche, A. A., Heber, M. F., Abruzzese, G. A., Ferrer, M. J., Telleria, C. M., & Motta, A. B. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111045 · Cited by 8
Metadata
- Authors
- Sirmans, S. M., Weidman-Evans, E., Everton, V., & Thompson, D.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2012-02-28
- Volume
- 46
- Issue
- 3
- Pages
- 403-418
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2150509846
- Cited by
- 24
- References
- 28
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polycystic Ovary Syndrome and Chronic Inflammation: Pharmacotherapeutic Implications. https://app.cochat.ai/papers/10.1345/aph.1q514
- The paper
- Sirmans, S. M., Weidman-Evans, E., Everton, V., & Thompson, D. (2012). Polycystic Ovary Syndrome and Chronic Inflammation: Pharmacotherapeutic Implications. Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1q514
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.